• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

UKCTOCS RCT Results: General Population Screening for Ovarian and Tubular Cancer

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Among a general population, Menon et al. (The Lancet, 2021) compared 2 ovarian cancer screening approaches (multimodal and ultrasound only)

METHODS:

  • Randomized controlled trial
    • UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)
    • Recruited between April 2001 and September 2005
  • Participants
    • Postmenopausal
    • 50 to 74 years
    • Excluded: Bilateral oophorectomy | Previous ovarian or active non-ovarian malignancy | Increased familial ovarian cancer risk
  • Interventions
    • Annual multimodal screening (MMS): Serum CA125 measurements using the ‘risk of ovarian cancer’ (ROCA) calculation | Triaged to normal (annual screening); intermediate (repeat CA125 ROCA test in 3 months); elevated (repeat CA125 ROCA test and transvaginal ultrasound (TVS) as a second-line test in 6 weeks)
    • Annual transvaginal ultrasound screening (USS): Primary screening done with TVS | Classified as normal (annual screening); unsatisfactory (repeat in 3 months); abnormal (scan with a senior ultrasonographer within 6 weeks)
    • No screening
  • Study design
    • Participants were randomly allocated, in a 1:1:2 ratio, to an intervention group
    • Follow-up was through national UK registries
    • Analyses were by intention to screen: Comparing MMS and USS separately with no screening
    • Masking: Investigators and participants were aware of screening type but outcomes review committee were not
  • Primary outcome
    • Death due to ovarian or tubal cancer (WHO 2014 criteria)

RESULTS:

  • 202,562 women
    • MMS group: 25.0% | USS group: 25.0% | no screening group: 50.0%
    • Median follow-up of 16.3 (IQR 15.1 to 17.3) years
  • 2055 total women were diagnosed with tubal or ovarian cancer
    • MMS: 1.0% of the group
    • USS: 1.0% of the group
    • No screening: 1.0% of the group
  • Compared with no screening, the MMS group experienced
    • Increased stage I incidence: 47.2% (95% CI, 19.7 to 81.1)
    • Decreased stage IV incidence: -24.5% (95% CI, -41.8 to -2.0)
  • Overall the incidence of stage I or II disease was higher in the MMS group compared to the no screening group
    • 39.2% (95% CI, 16.1 to 66.9)
  • Incidence of stage III or IV disease was lower in the MMS group compared to the no screening group
    • -10.2% (95% CI, −21.3 to 2.4)
  • Tubal and ovarian cancer mortalities
    • MMS: 0.6%
    • USS: 0.6%
    • No screening: 0.6%
  • There was no significant reduction in ovarian and tubal cancer deaths in the MSS (P=0.58) or USS (P=0.36) group compared to no screening

CONCLUSION:

  • While there was an approximately 10% reduction in incidence of stage III or IV ovarian cancers with MSS screening, there was no difference in ovarian cancer mortality with either screening type
  • The authors state

General population screening for ovarian and tubal cancer with either of the screening strategies cannot be recommended based on evidence to date

The changes in stage distribution in the MMS group did not translate into mortality reduction, emphasising the importance of having disease-specific mortality as the primary outcome in ovarian cancer screening trials

Achieving a mortality reduction will require a screening strategy that can detect ovarian and tubal cancer even earlier and in a larger proportion of women than we were able to achieve

In the MMS group of UKCTOCS, it seems probable that the cancers shifted to an earlier stage had an intrinsic poor prognosis, which was not altered by earlier detection and the available treatments for early stage disease

Learn More – Primary Sources:

Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Screening for Ovarian Cancer – Fantasy or Reality?
Could Existing Ultrasound Predictive Models be Used to Better Predict Ovarian Cancer? 
Do Contraceptives Decrease Risk for All Ovarian Cancers?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site